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540 The Journal of Thoracic and Cardbjectives: The rationale and design of the Surgical Treatment for Ischemic Heart
ailure trial is described. Before the Surgical Treatment for Ischemic Heart Failure
rial, less than 1000 patients with ischemic cardiomyopathy had been studied in
andomized comparisons of medical therapy versus coronary artery bypass grafting.
rial data reflect how these therapies were delivered more than 20 years ago and do
ot indicate the relative benefits of medical therapy versus coronary artery bypass
rafting in contemporary practice.
ethods: Randomization of consenting patients with heart failure, left ventricular
jection fraction of 0.35 or less, and coronary artery disease is based on whether patients
re judged by attending physicians to be candidates only for coronary artery bypass
rafting or can be treated with medical therapy without coronary artery bypass grafting.
atients eligible for surgical ventricular reconstruction because of significant anterior
all akinesis or dyskinesis but ineligible for medical therapy are randomly assigned to
oronary artery bypass grafting with or without surgical ventricular reconstruction.
atients eligible for medical therapy are randomly assigned between medical therapy
nly and medical therapy with coronary artery bypass grafting. Patients eligible for all
are randomly assigned evenly to medical therapy only, medical therapy and coronary
rtery bypass grafting, or medical therapy and coronary artery bypass grafting and
urgical ventricular reconstruction. Major substudies will examine quality of life, cost-
ffectiveness, changes in left ventricular volumes, effect of myocardial viability, se-
ected biomarkers, and selected polymorphisms on treatment differences.
esults: Enrollment is now complete in both STICH hypotheses. Follow-up will
ontinue until sufficient end points are available to address both hypotheses with at
east 90% power. The primary outcome of hypothesis 2 is expected to be reported
n 2009. The primary outcome of hypothesis 1 is expected to be reported in 2011.
onclusions: The Surgical Treatment for Ischemic Heart Failure trial is a National
eart, Lung, and Blood Institute–funded multicenter international randomized trial
ddressing 2 specific primary hypotheses: (1) coronary artery bypass grafting with
ntensive medical therapy improves long-term survival compared with survival with
edical therapy alone, and (2) in patients with anterior left ventricular dysfunction,
urgical ventricular reconstruction to a more normal left ventricular size plus coronary
rtery bypass grafting improves survival free of subsequent hospitalization for cardiac
ause when compared with that with coronary artery bypass grafting alone.
 
he revascularization of patients with coronary artery disease (CAD) wit
ventricular (LV) systolic dysfunction (SD) and symptomatic heart failure (HF)
has been the subject of much debate and surprisingly little research over the past0 years.1,2 Our current understanding of how best to treat these patients stems from
iovascular Surgery ● December 2007
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A
CDubset analyses of the coronary artery bypass grafting (CAB-
)–medicine clinical trials performed in the 1970s and early
980s and analyses of large registries of patients from the
ame era.3-7 Although such analyses have generally de-
nstrated that patients with more advanced CAD and more
evere LV dysfunction derive larger benefit from CABG
elative to medical therapy (MED), in practice both cardi-
logists and surgeons have substantial uncertainty about
hether these projected benefits are counterbalanced by the
ncreased early risks of the surgical approach.
In 2002, the National Heart, Lung, and Blood Institute
NHLBI) funded the Surgical Treatment for Ischemic Heart
ailure (STICH) trial to address 2 pressing clinical and
olicy questions regarding the management of patients with
F with surgically revascularizable CAD and decreased LV
unction: (1) Is contemporary CABG surgery superior to
ontemporary medical/secondary prevention therapy in pro-
onging survival in these patients? (2) Among patients with
ignificant anterior wall dysfunction, does the addition of
urgical ventricular reconstruction (SVR) to CABG im-
rove hospitalization-free survival?
aterials and Methods
tudy Design
n the absence of definitive data on the value of CABG in high-risk
atients with LVSD, wide diversity exists among providers about
ow to select patients. Moreover, many patients who might be
ABG candidates also have dominant anterior akinesia or dyski-
esia that might be reasonable to reconstruct surgically at the time
f CABG.8 Therefore the STICH trial was designed to let ph-
ians first determine whether potential STICH patients were ame-
able to CABG after their routine clinical assessment. A threshold
V ejection fraction (EF) of 0.35 or less was established, with no
ower limit set to preclude study entry. Physicians are encouraged
o use any cardiac testing necessary to decide whether an individ-
al patient is a candidate for CABG, SVR, or both. This philoso-
hy encourages the use of standard practice to identify patients for
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CAD  coronary artery disease
CASS  Coronary Artery Surgery Study
EF  ejection fraction
H1  hypothesis 1
H2  hypothesis 2
HF  heart failure
LV  left ventricular
MED medical therapy
NHLBI National Heart, Lung, and Blood Institute
PCI  percutaneous coronary intervention
SD  systolic dysfunction
SVR  surgical ventricular reconstructionhom responsible physicians are at equipoise about MED, CABG, a
The Journal of Thoracicnd CABG with SVR and ensures that the STICH cohort has
haracteristics that now pose the greatest uncertainty in clinical
ecision making for patients with ischemic cardiomyopathy.
oreover, all information now commonly used by clinicians in
eciding on surgical treatment for a subset of patients with isch-
mic cardiomyopathy will be available so that the value added by
ach component to the decision-making process can be evaluated
Table 1).
Subjects meeting the broad inclusion criteria of CAD amenable
o CABG with an LVEF of 0.35 or less, without a specific
xclusion, are segregated into 3 strata (A, B, and C) depending on
nvestigator-determined suitability for continued MED alone and
ligibility for SVR (Figure 1). Eligibility for MED alone is d
y the investigator but generally excludes patients with an intralu-
inal left main coronary artery stenosis of 50% or greater or
evere disabling angina (Canadian Cardiovascular Society Class
III) unresponsive to nonsurgical interventions. Eligibility for
VR is defined as dominant LV akinesia or dyskinesia amenable to
VR. Stratum A subjects are defined as suitable for MED with or
ithout CABG, and consenting patients are randomly assigned in
1:1 ratio between MED alone or with CABG. Stratum B subjects,
efined as eligible for all 3 treatment options, are randomly as-
igned 1:1:1 to either MED alone, MED with CABG, or MED with
ABG and SVR. Subjects eligible for CABG with and without
VR are randomly assigned 1:1 in stratum C to either CABG or
ABG with SVR. After stratum eligibility is established and
nformed consent is obtained, treatment allocation is made to a
pecific therapy based on an undisclosed permuted block random-
zation scheme.
tudy Population
he STICH trial is designed to enroll at least 2000 men and
omen aged 18 years and older who have CAD amenable to
evascularization and LVSD defined by a clinically determined
VEF of 0.35 or less. STICH trial entry criteria are summarized in
able 2. Patients awaiting a planned percutaneous coronary i
ention (PCI) to treat symptomatic CAD within the next 30 days
re not eligible, although previous PCI is not an exclusion. Al-
hough planned operative treatment of the aortic valve excludes
otential candidates, the decision to pursue operative management
f any other valves, specifically the mitral valve, is left to the
iscretion of responsible physicians and surgeons.
Baseline and follow-up studies. After obtaining informed con-
ent, baseline demographics, physical examination, laboratory
ata, and medical details, including procedural history and details,
re collected, and all patients undergo any remaining requisite
aseline studies (Table E1). Patients eligible for MED alone
olled into strata A and B undergo baseline radionuclide perfusion
nd viability imaging and a modified Bruce protocol exercise
tress test, if they are able to exercise. SVR-eligible patients
nrolled into strata B and C preferably undergo baseline cardio-
ascular magnetic resonance or gated single photon emission
omputed tomographic perfusion imaging with follow-up at 4 and
4 months to assess postoperative size, shape, and function.
All STICH subjects will undergo echocardiography and blood
ampling for neurohormonal, cytokine, and genetic analyses; a
etailed quality-of-life assessment; and a 6-minute walk test, if
ppropriate, based on subject status. These baseline studies are
and Cardiovascular Surgery ● Volume 134, Number 6 1541
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A
CDepeated in 4 months, with further repeat echocardiographic anal-
sis performed at 24 months. Continuing assessment of quality of
ife and exercise capacity for all patients will occur at yearly
ntervals after randomization. Table E2 outlines STICH follow
tudies. Details of core laboratory testing protocols are available at
ww.stichtrial.org.
Medical therapy. The STICH Medical Therapy Committee is
andated to regularly review evidence and redefine optimal MED
hen necessary for all STICH subjects, regardless of randomiza-
ion strata or treatment. Unless contraindicated, optimal MED
ncludes angiotensin-converting enzyme inhibitor, angiotensin re-
eptor blocker, or both; -blocker; aldosterone antagonist; and
ntiplatelet agents adjusted to optimal doses within 30 days after
andomization. Statin, diuretic, and digitalis use will be individu-
lized to patient-specific indications. The use of implantable defi-
rillators is encouraged as part of MED and should be used in
ompliance with standard guidelines. A lead cardiologist at each
ite is responsible for ensuring high-quality MED for all patients,
ncluding those treated with surgical intervention.
Surgical therapy. Subjects randomly assigned to either CABG
r CABG with SVR will receive the protocol-determined inter-
ention no later than 14 days after randomization. CABG is
erformed by using at least 1 internal thoracic conduit, unless
navailable or inadequate. Use of cardiopulmonary bypass for
ABLE 1. Major STICH hypotheses
Primary hypotheses
H1: Coronary revascularization hypothesis
● Improvement in myocardial perfusion by CABG combined with
H2: LV restoration hypothesis
● In patients with dominant anterior wall LV akinesia or dyskines
MED improves long-term survival free of cardiac hospitalization
Major secondary hypotheses
● Presence and extent of dysfunctional but viable myocardium, a
echocardiography, or both, will identify patients with greatest s
● Echocardiographic assessment of LV systolic and diastolic dys
baseline will define patient subgroups that derive substantial im
with MED and CABG compared with MED alone.
● Surgical intervention with CABG will lead to greater sustained
indices of LV systolic and diastolic dysfunction, hemodynamics
● Assessment of myocardial ischemia at baseline by means of ra
patients with a survival benefit of MED and CABG compared w
● MED and CABG with SVR will lead to more improvement in LV
and 24 months compared with MED and CABG without SVR.
● CMR assessment of the baseline LV sphericity index will add in
regardless of treatment assignment, and MED and CABG with
with MED and CABG alone.
● Extent of neurohormonal and proinflammatory cytokine activati
survival benefit from MED and CABG with or without SVR com
● Presence of a favorable genotype (eg, low ACE gene expressio
likely to have long-term improvement in cardiovascular morbidi
● MED and CABG will lead to incremental cost-effectiveness ass
added relative to MED alone.
● MED and CABG will lead to greater improvement in health-rela
TICH, Surgical Treatment for Ischemic Heart Failure trial; H1, hypothesis 1
; LV, left ventricular; SVR, surgical ventricular reconstruction; ACE, angioABG is left to the discretion of the surgeon. Patients with a
542 The Journal of Thoracic and Cardiovascular Surgery ● Dececondary mitral regurgitation judged to require mitral valve repair
r replacement might undergo this procedure, although this is not
andated by protocol. The SVR typically occurs after CABG by
eans of any acceptable reconstruction method that consistently
ncreases LVEF and decreases end-systolic volume. The general
perative technique for SVR has been previously described.8 Use
f a sizing device to judge appropriate LV chamber size and the
ecision of whether and how to patch the LV closure site are left
o the operating surgeon.
Before and during hypothesis 2 (H2) patient recruitment, mul-
iple educational opportunities will be made available to cardiac
urgeons to refine surgical decision making and operative tech-
iques for patients undergoing SVR. A lead cardiac surgeon at
ach site is responsible for initially certifying that all STICH
urgeons meet qualification standards set by the Surgical Therapy
ommittee and for maintaining a high quality of surgical care for
he duration of the trial. The most experienced cardiac surgeons at
ach site are certified as eligible to operate on randomized patients.
he minimum requirement for certification is evidence of 25
atients undergoing CABG with LVEFs of 0.40 or less who were
perated on with 5% or lower mortality. Before cardiac surgeons
re certified to perform SVR on a randomized patient, they are
equired to perform at least 5 SVR procedures without a periop-
rative death and demonstrate consistent LV volume reduction
improves long-term survival compared with MED alone.
shape and size optimization by SVR combined with CABG and
pared with CABG and MED without SVR.
fined by radionuclide imaging, dobutamine stress
al advantage of MED and CABG compared with MED alone.
ion, cardiac hemodynamics, and valvular regurgitation at
ement or incur substantial risk in all-cause mortality if treated
vements at 4 and 24 months in echocardiography-derived
valvular regurgitation when compared with MED alone.
uclide perfusion imaging during rest and stress will identify
ose treated with MED alone.
systolic volume index measured serially at baseline, 4 months,
ndent prognostic information beyond LV end-systolic index,
will lead to an improved LV sphericity index when compared
ill identify the patient subgroup most likely to derive substantial
with MED alone.
h adenosine expression) will identify the patient subgroup most
d mortality.
d as cost/life year added and cost/quality-adjusted life year
uality of life
G, coronary artery bypass grafting; MED, medical therapy; H2, hypothesis
n-converting enzyme.MED
ia, LV
com
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A
CDPatient follow-up. The first follow-up for clinical status occurs
t hospital discharge or at 30 days after randomization, whichever
omes first. Participants are subsequently seen at 4-month intervals
fter randomization for the first year and no less than every 6
onths after year 1. At these visits, interval assessments of HF and
ngina symptom status, current use of medications, and clinical
nd point data, including hospitalizations and procedures since the
revious visit, are documented. Regardless of therapy received, all
tudy participants are followed in this manner until study
ompletion.
tatistical Issues
Hypothesis 1 power. All patients enrolled into stratum A and
wo thirds of patients enrolled into stratum B, those assigned to
ED with or without CABG, comprise the hypothesis 1 (H1)
tudy cohort. All-cause mortality is the primary end point of H1.
1 power estimates were based on an estimated 3-year mortality
ate of 25% in the MED arm of the trial. This rate is slightly lower
han the mortality observed in the control arm (no implantable
ardioverter defibrillator implanted) of the ischemic cardiomyop-
thy cohort of the Sudden Cardiac Death in Heart Failure T9
pproximately 400 deaths are required to achieve 90% statistical
ower for detecting a treatment difference consisting of a 25%
eduction in mortality with MED with CABG. These 400 deaths
re projected to occur if at least 1000 H1 patients are followed for
n average of 6.5 years or 1200 patients are followed for an
verage of 5.5 years.
Hypothesis 2 power. All patients randomly assigned to stratum
and the two thirds of patients entered into stratum B assigned to
ither CABG or CABG with SVR comprise the H2 study cohort.
composite end point of survival free of cardiac hospitalization
as chosen for H2 because no data exist to suggest that adding
VR to CABG improves survival over CABG alone. Moreover,
his composite end point has validity for patients who would be
ikely to consent to adding SVR to a planned CABG. The planned
nrollment of 1000 patients into H2 provides a 90% power to c
The Journal of Thoracicetect a 20% reduction in mortality and cardiac hospitalization by
he addition of SVR to CABG, assuming that the 3-year event rate
or those treated with CABG alone is 45% or higher.
Treatment crossovers. Crossovers between MED to CABG or
ABG and SVR are anticipated within the first year because of the
ynamic nature of coronary disease and the potential for deterio-
ating symptoms unresponsive to standard MED and requiring
ymptomatic relief. Patients randomly assigned to CABG and SVR
ight also not receive SVR because of intraoperative decisions
hat maximize patient safety. PCI is not regarded as a treatment
rossover but rather as downstream medical care associated with
ny of the treatment strategies tested in the STICH trial. The
ample sizes for both H1 and H2 allow for treatment crossovers of
s much as 20% without sacrificing power so long as the control
vent rates remain as projected.
Secondary end points. Secondary end points for both hypoth-
ses include all-cause mortality at 30 days, cardiovascular mortal-
ty, survival free of HF hospitalization, survival free of subsequent
evascularization, need for cardiac transplantation, need for an LV
ssist device, all-cause hospitalization, LV size, LV function, total
ealth care costs, cost-effectiveness, and quality of life. Other
mportant efficacy parameters that will be evaluated include fatal
nd nonfatal myocardial infarction, fatal and nonfatal stroke, sud-
en death with or without resuscitation, survival free of PCI, and
urvival free of CABG.
Approach to data analysis. The primary efficacy analyses will
e performed according to the principle of intention to treat; that is,
atients will be analyzed (and end points attributed) according to
he treatment arm to which they were randomly assigned, regard-
ess of subsequent crossover or nonadherence to the assigned
reatment. Statistical comparisons will be performed by using
-sided significance tests. For the primary comparisons of MED
ersus CABG in H1 and CABG versus CABG with SVR in H2,
he log-rank test will be used, adjusting for the stratum in which
he patients were enrolled.10 Cumulative event rates will be c-
Figure 1. Surgical Treatment for Ischemic Heart
Failure trial stratum and treatment assignment.
CAD, Coronary artery disease; EF, ejection frac-
tion; SVR, surgical ventricular reconstruction;
MED, medial therapy; CABG, coronary artery by-
pass grafting.ulated according to the Kaplan–Meier method.11 Event (or cen-
and Cardiovascular Surgery ● Volume 134, Number 6 1543
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A
CDoring) times for all patients will be measured from the time of
andomization (time zero). Relative risks will be expressed as
azard ratios with associated confidence intervals and will be
erived from the Cox proportional hazards model.12,13 The Cox
odel will also be used in the assessment of treatment differ-
nces and analyses for many of the secondary end points.
nterim analyses of the data will be performed and reviewed by
n independent Data and Safety Monitoring Board appointed by
he NHLBI. Interim treatment comparisons will be monitored
ith the use of 2-sided, symmetric O’Brien–Fleming bound-
ries generated with the Lan–DeMets -spending function ap-
ABLE 2. STICH trial entry criteria
Inclusion criteria*
● Men
● Women not of childbearing potential
● Age 18 y
● LVEF 0.35 measured by means of contrast magnetic
resonance ventriculography, gated SPECT ventriculography,
echocardiography, or contrast ventriculography within 3 mo of
trial entry
● CAD suitable for revascularization
Exclusion criteria†
● Failure to provide informed consent
● Aortic valvular heart disease indicating need for aortic valve
repair or replacement
● Cardiogenic shock (within 72 h of randomization) defined by
need for IABP support or requirement of intravenous inotropic
support
● Plan for PCI of CAD
● Recent acute MI judged to be an important cause of LV
dysfunction
● History of 1 prior CABG
● Noncardiac illness with a life expectancy of 3 y
● Noncardiac illness imposing substantial operative mortality
● Conditions/circumstances likely to lead to poor treatment
adherence (eg, history of poor compliance, alcohol or drug
dependency, psychiatric illness, and no fixed abode)
● Prior heart, kidney, liver, or lung transplantation
● Current participation in another clinical trial in which the
patient is taking an investigational drug or receiving an
investigational medical device
MED therapy eligibility criteria
● Absence of left main CAD defined by intraluminal stenosis
50%
● Absence of Canadian Class III angina or greater (angina
markedly limiting ordinary activity)
SVR eligibility criterion
● Dominant akinesia or dyskinesia of anterior LV wall amenable
to SVR
TICH, Surgical Treatment for Ischemic Heart Failure trial; LVEF, left
entricular ejection fraction; SPECT, single photon emission computed
omography; CAD, coronary artery disease; IABP, intra-aortic balloon
ump; PCI, percutaneous coronary intervention; MI, myocardial infarction;
V, left ventricular; CABG, coronary artery bypass grafting; MED, medical
herapy; SVR, surgical ventricular reconstruction. *Patients might qualify
or inclusion in the study. †None of these can exist at randomization.roach to group-sequential testing.14,15 (
544 The Journal of Thoracic and Cardiovascular Surgery ● Dectudy Leadership
he STICH trial is an investigator-initiated, international study
unded by the NHLBI of the National Institutes of Health. The
TICH Steering Committee is comprised of principal investigators
t all enrolling sites. An executive council is empowered by the
teering Committee to make day-to-day decisions (Appendix 
owever, all major executive council decisions are subject to
eview and approval of the Steering Committee.
Trial operations, site management and monitoring, statistical
lanning, and data analysis are being coordinated at the Duke
linical Research Institute of Duke University in Durham, North
arolina. An end point classification committee blindly adjudi-
ates all hospitalizations during follow-up. This committee func-
ions independently of the operational team and is chaired by a
ardiovascular specialist without direct access to potential STICH
atients. A fully independent Data and Safety Monitoring Board
Appendix E2) has been empowered to review unblinded sa
nd efficacy data no less than twice yearly by using the prespeci-
ed early termination rules described in the previous section.
esults
nrollment is now complete in both STICH hypotheses.
ollow-up will continue until sufficient end points are avail-
ble to address both hypotheses with at least 90% power.
he primary outcome of hypothesis 2 is expected to be
eported in 2009. The primary outcome of hypothesis 1 is
xpected to be reported in 2011.
iscussion
ationale for Contemporary Evaluation of Survival
enefit Associated With Addition of CABG to MED in
atients With Ischemic Cardiomyopathy
andomized trials of CABG surgery enrolling 2234 patients
etween 1971–1979 established the safety of surgical re-
ascularization in patients with preserved LV systolic func-
ion and chronic stable angina.5 Improved survival afte
ABG compared with that with MED alone was shown for
atients with angina and flow-limiting stenoses of the left
ain coronary artery or multiple coronary arteries, espe-
ially in patients with severe stenosis of the proximal left
nterior descending coronary artery. The Coronary Artery
urgery Study (CASS) was the only one of these 7 early
tudies to stratify randomization of the 780 patients enrolled
ased on LVEF (0.35–0.50 vs 0.50), angiographic extent
f CAD (1-, 2-, or 3-vessel stenosis), and presence or
bsence of angina at the time of enrollment. At the conclu-
ion of 10 years of follow-up, 82 (21%) of 390 patients
andomly assigned to receive MED alone had died, and 70
18%) of 390 patients randomly assigned to receive MED
lus CABG had died (P  .25).16 The subgroup of patien
ith an LVEF of 0.35 to 0.50 was the only stratified
ubgroup in CASS to show a significant survival differ-
nce.3 Of the 160 patients in CASS who had LVSD
38%) of the 82 MED-treated patients died, whereas 16
21%) of the 78 patients who underwent CABG (P  .01)
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A
CDied. However, the 54-patient subset of CASS who had
VSD but no angina did not derive a statistical survival
dvantage from CABG (P  .12).
Since the initial description of the clinical syndrome of
schemic cardiomyopathy more than 3 decades ago,17 the
linical care of patients with CAD and LVSD has under-
one a dramatic evolution. When the last patient was ran-
omized between CABG and MED during the time of
ASS enrollment, MED for patients with HF, LVSD, and
AD was limited to digitalis and diuretics, which are med-
cations now known to have a neutral effect on mortality.
urrent American College of Cardiology/American Heart
ssociation guidelines highlight the major advances in
harmacotherapy and device therapy that have improved the
uality of life and survival of patients with CAD, HF, and
VSD.18 However, the evidence base remains deficient
dentifying which, if any, patients with CAD and LVSD
hould receive revascularization. Although specific clinical
roblems in this population, such as severe angina, are used
o decide on revascularization strategies, the vast majority
f patients with ischemic cardiomyopathy have limited or
o angina and fall into a gray zone, where clear evidence for
dding CABG to MED is either absent or outdated. Thus,
ivergent views have evolved among clinicians since the
eports of the CASS data as to the most appropriate diag-
ostic and management strategy for patients with ischemic
ardiomyopathy. Table E318-22 summarizes current guide-
ine recommendations as they relate to the selection of
ABG as a treatment option for patients with poor LV
unction.
The weight of observational data suggests that HF and
VSD remain associated with a higher risk of post-CABG
omplications and mortality, and although increasing num-
ers of patients with LVSD and angina are referred to
ABG, it might remain underused.23,24 Of the 24,959 pa-
ients screened and entered into the CASS registry from
975-1979, 751 patients had severe LVSD (as defined by an
VEF 35%), 231 patients underwent CABG, and 420
atients remained on MED.4 Overall 5-year survival fa-
ored MED. However, the subset of patients with an LVEF
f less than 26% had a survival advantage demonstrated for
he 82 patients who received CABG compared with the 172
atients treated medically (P  .006). The CASS registry
ABG group had more angina and less severe LVSD than
he CABG cohort in the randomized trial. The CASS reg-
stry patients undergoing CABG presenting with angina had
mproved survival free of functional limitation, but pa-
ients with predominant HF did not. A large observa-
ional series summarized outcomes for 1391 patients with
AD and an LVEF of less than 40% who underwent
iagnostic coronary angiography from 1969 –1994.7 Af-
er adjustment for baseline differences, the 339 patients
ho received CABG had a better survival rate than the t
The Journal of Thoracic052 patients who received only MED. However, unlike
ASS registry patients, this observed survival advantage
ccurred in all patients, regardless of LVEF and HF status.
he perspective that CABG use in patients with LVSD
hould be confined only to the patient subset with ongoing
ngina continues to influence treatment guidelines today.
hould the STICH trial show that revascularization provides
urvival benefit beyond that of modern MED, not only will
ABG be used more aggressively in patients with LVSD
nd CAD amenable to CABG, but it will also indicate the
eed to evaluate for CAD in all patients who present with
F and LVSD.
ationale for a Prospective Assessment of
yocardial Viability
iability testing by various modalities is currently used by
any clinicians to select patients for surgical intervention.
ositron emission tomography has been considered by
any to be the gold standard, but high cost and lack of
idespread availability has led to limited use.25 Thallium-
r technetium-based nuclear scintigraphy, using one of
any rest or stress imaging protocols, has become more
idespread and has acceptable sensitivity and specificity26
ecause it is readily available, dobutamine stress echocar-
iography to demonstrate augmentation of the contractile
esponse has become the test of choice for assessing tissue
iability at many institutions.27 Although not as widel
vailable, delayed contrast enhancement on cardiovascular
agnetic resonance scanning is a reliable method to detect
onviable myocardium.28 Although guidelines recommend
hat the presence or absence of viable myocardium can be
onsidered in the decision as to whether revascularization
hould be recommended,18-21 the strength of this recom-
endation varies among the individual guidelines (Ta
3). Therefore extensive heterogeneity exists on how c
cally available structural and functional imaging is incor-
orated into treatment decisions for patients with CAD and
VSD.
Viable myocardium in patients with LVSD and CAD
ppears to predict contractile recovery in dysfunctional
yocardial segments, regardless of whether patients receive
ED alone or CABG.29 Although no studies have validat
he use of viability testing regardless of the imaging modal-
ty in a prospective randomized trial with a survival end
oint, many retrospective nonrandomized observational se-
ies have been published that evaluated the association
etween the results of viability testing and short-term clin-
cal outcomes. Systematic reviews30,31 suggest that, when
resent, myocardial viability is associated with improved
hort-term (18 month) survival in patients referred to
ABG, but conversely, the absence of viability is not nec-
ssarily associated with disparate outcomes between medi-
ally and surgically treated patients. Unfortunately, a mul-
itude of confounding factors, including the lack of standard
and Cardiovascular Surgery ● Volume 134, Number 6 1545
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A
CDefinitions for viability, the heterogeneous nonrandomized
opulations studied, and the lack of uniform MED received,
imit the applicability of these data to current practice.
lthough the use of viability imaging is predicated on an
bility to predict functional recovery, failure to improve LV
unction is not necessarily associated with a worse clinical
utcome.32 Because CABG in patients with LVSD con-
es to be associated with substantial operative risk, when
nd how viability imaging is used to reliably predict long-
erm outcomes are critical questions that require definitive
nswers.
ationale for SVR as an Adjunct to CABG for
atients With Predominant Anterior Akinesia
urgical reconstruction of akinetic, dyskinetic, or aneurys-
al segments might theoretically decrease LV wall stress,
yocardial oxygen consumption, and stroke volume while
reserving or improving contractile function in the remain-
ng ventricle. In the CASS registry population of LVSD,
ore than 30% of the patients who underwent CABG
nderwent concomitant ventricular reconstruction surgery4
hese early linear plications or resections of dyskinetic scar
ommonly deformed the LV cavity into a box-like shape
nd did not consistently improve ventricular performanc33
ntracavity reconstruction techniques were developed for
epairing defects left by aneurysmal resection that reduced
V cavity size but retained a more elliptical configuration of
he ventricle.34 Dor and colleagues8 advocated the use o
VR not only in patients with dyskinetic scar but also in
hose with only akinetic myocardial segments. A preserved
picardial covering of myocardial fibrosis might make these
kinetic zones appear normal at the time of cardiac opera-
ion, but palpable thinning usually can be appreciated in the
rrested decompressed heart. Unlike earlier LV aneurys-
ectomy that removed myocardial scarring or the Batista
peration35 that reduced LV size by means of excisio
ortions of the LV wall, the objective of the SVR operation
s to reshape and decrease the size of the left ventricle by
ecreasing the circumference of the endocardial scar
hrough an incision in normal epicardium. Myocardial scar
s occasionally excised during SVR, but, commonly, no
issue is removed at the time of the operation. The intrinsic
car or an extrinsic patch can be used during closure of the
eft ventriculotomy to decrease linear wall tension and avoid
he restrictive physiology of undersizing the left ventricle.
The RESTORE registry group reported on 1198 patients
ho underwent SVR at 11 centers, with a 5.1% operative
ortality and an 88% 18-month survival rate for all pa-
ients.36 A recent report from the Society of Thoracic -
ery database37 suggests that SVR is being performed w
ncreasing frequency for the treatment of patients with HF,
AD, and LVSD; however, the perioperative risk might be
ore substantial. In this 2002–2004 US sample, 731 pa-ients underwent SVR at 141 of 576 reporting centers. The
1
546 The Journal of Thoracic and Cardiovascular Surgery ● Decerioperative 30-day outcomes were 9.3% for mortality and
3.5% for any major complication. Use of SVR as an
djunct to CABG for patients with LVSD cannot yet be
ustified on firm evidence because no reports are available
omparing outcomes of CABG and SVR with CABG alone
n similar populations. H2 of the STICH trial was designed
o address this important question.
urrent Status of the STICH Trial
he first patient was randomized into the STICH trial in
uly 2002. Since then, the STICH Steering Committee has
pproved 3 protocol amendments to facilitate successful
ompletion of trial enrollment (Appendix E3). Randomi
ion of 1000 planned subjects into H2 was completed in
anuary 2006 and led to the closure of strata B and C to
urther enrollment. This represents the largest randomized
omparison of 2 cardiac surgical strategies. H2 primary end
oint results are expected to be published in 2009. In June
006, STICH enrollment into H1 surpassed the CASS study
s the largest comparison of cardiac surgical and medical
pproaches to chronic CAD. H1 completed enrollment in
ay 2007. Published H1 results are anticipated by 2011.
We thank Drs Eugene Braunwald, Myron L. Weisfeldt, and
obert M. Califf for their critical assistance during the initial
lanning of the STICH trial and Elizabeth E. Schramm for her
ditorial assistance.
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CDPPENDIX E1. Surgical Treatment for Ischemic Heart Failure Executive Council
tudy Chair: Jean L. Rouleau, MD
rincipal Investigator, Clinical Coordinating Center: Robert H. Jones, MD
rincipal Investigator, Data Coordinating Center: Kerry L. Lee, PhD
irector, Global Trial Operations: Eric J. Velazquez, MD
hair, Core Laboratory Committee: Jae K. Oh, MD
o-Chair, Surgical Therapy Committee: Robert H. Michler, MD
o-Chair, Medical Therapy Committee: Christopher M. O’Connor, MD
rogram Officer, National Heart, Lung, and Blood Institute: George Sopko, MD
PPENDIX E2. Surgical Treatment for Ischemic Heart Failure trial Data and Safety Monitoring Board
hair: Sidney Goldstein, MD
elicia Cohn, MD
athryn Davis, PhD
harles Francis, MD
ark Hlatky, MD
cott Rankin, MD
obert Robbins, MD
arry Zaret, MD
PPENDIX E3. Summary of Surgical Treatment for Ischemic Heart Failure trial design changes introduced
y revisions to the original protocol
Protocol version 1:
January 18, 2002
Protocol version 2:
February 24, 2003
Protocol version 3:
November 1, 2004
Protocol version 4:
May 1, 2006
ntry criteria Symptomatic HF  NYHA class II in
previous 3 mo required
NYHA class I-IV eligible No further change No further change
SVR eligibility: SVR eligibility: No further change No further change
● ESVI  60 mL/m2
● anterior akinesia  35%
● inferior akinesia absent
● right and left circumflex coronary
artery graftable
● Investigator
determined dominant
akinesia or
dyskinesia of the
anterior wall
amenable to SVR
LVEF  0.35 measured by CMR,
gated SPECT, contrast
ventriculography at site or
echocardiography core laboratory
reading
Echocardiography core
laboratory reading
requirement dropped;
any site reading of
LVEF  0.35
regardless of
modality before
randomization
acceptable
No further change No further change
Any MI within 30-d exclusion MI judged to be an
important cause of
LVSD within 30-d
exclusion
No further change No further change
Refractory potentially lethal
ventricular arrhythmia exclusion
Potentially lethal
ventricular arrhythmia
exclusion dropped
No further change No further change
ore
laboratory
studies
RN stress perfusion study required
on strata A and B patients
RN stress perfusion
study strongly
encouraged but not
No further change No further changerequired
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CDPPENDIX E3. Continued
Protocol version 1:
January 18, 2002
Protocol version 2:
February 24, 2003
Protocol version 3:
November 1, 2004
Protocol version 4:
May 1, 2006
Baseline RN viability imaging
required for strata A and B
subjects; DSE performed as
ancillary study
— Baseline RN, DSE,
or both viability
strongly
encouraged for
strata A and B
subjects
No further change
Blood sample for NCG studies
required of all subjects
— Blood sample for
NCG studies
strongly
encouraged but
not required
No further change
ample size Hypothesis 1 sample size 2000
patients
— Hypothesis 1
sample size
reduced
No further change
requency of
follow-up
visits
Follow-up visits required every 4 mo — — Follow-up visits
required every 4
mo during first
year and then
every 6 mo
thereafter
tudy duration Follow-up to close December 31,
2008
— — Study termination
end point driven
(400 primary
events in
hypothesis 1
cohort)
TICH, Surgical Treatment for Ischemic Heart Failure trial; HF, heart failure; NYHA, New York Heart Association; SVR, surgical ventricular reconstruction;
SVI, end-systolic volume index; LVEF, left ventricular ejection fraction; CMR, cardiovascular magnetic resonance; SPECT, single photon emission
omputed tomographic; MI, myocardial infarction; LVSD, left ventricular systolic dysfunction; RN, radionuclide; DSE, dobutamine stress echocardiography.The Journal of Thoracic and Cardiovascular Surgery ● Volume 134, Number 6 1547.e2
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CDABLE E1. STICH baseline evaluation studies
tratum A Stratum B Stratum C
ll consenting patients
Echo to Core Echo to Core Echo to Core
QOL to Core QOL to Core QOL to Core
EuroQOL to Core EuroQOL to Core EuroQOL to Core
CMR, gated SPECT, or Echo for LV function CMR, gated SPECT, or Echo for LV function CMR, gated SPECT, or Echo for LV function
hen feasible
NCG blood to Core NCG blood to Core NCG blood to core
Myocardial viability to Core Myocardial viability to Core
atients able
6-min walk 6-min walk 6-min walk
Exercise stress Exercise stress Exercise stress
TICH, Surgical Treatment for Ischemic Heart Failure trial; Echo, Echocardiography; QOL, quality of life; CMR, cardiovascular magnetic resonance; SPECT,
ingle photon emission computed tomography; LV, left ventricular; NCG, neurohormonal, cytokine, and genetic analyses.
ABLE E2. STICH follow-up evaluation studies
nterval/patient
haracteristics Stratum A Stratum B Stratum C
mo
All patients Echo to Core; EuroQOL to Core Echo to Core; EuroQOL to
Core; V-gram to Core (CMR,
SPECT, or Echo)
Echo to Core; EuroQOL to
Core; V-gram to Core (CMR,
SPECT, or Echo)
When feasible NCG blood to Core NCG blood to Core NCG blood to Core
Patients able 6-min walk 6-min walk 6-min walk
2 mo
All patients EuroQOL to Core EuroQOL to Core EuroQOL to Core
Patients able 6-min walk 6-min walk 6-min walk
4 mo
All patients Echo to Core; EuroQOL to Core Echo to Core; EuroQOL to
Core; V-gram to Core (CMR,
SPECT, or Echo)
Echo to Core; EuroQOL to
Core; V-gram to Core (CMR,
SPECT, or Echo)
Patients able 6-min walk; exercise stress 6-min walk; exercise stress 6-min walk; exercise stress
6 mo
All patients EuroQOL to Core EuroQOL to Core EuroQOL to Core
Patients able 6-min walk 6-min walk 6-min walk
8 mo
All patients EuroQOL to Core EuroQOL to Core EuroQOL to Core
Patients able 6-min walk 6-min walk 6-min walk
TICH, Surgical Treatment for Ischemic Heart Failure trial; Echo, echocardiography; QOL, Quality of life; V-gram, ventriculogram; CMR, cardiovascular
agnetic resonance; SPECT, single photon emission computed tomography; NCG, neurohormonal, cytokine, and genetic analyses.
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CDABLE E3. Current recommendations relating to the selection of patients with poor LV function for CABG
uideline/indication
Classification
of recommendation
Level of
evidence
CC/AHA 2004 guideline update for CABG surgery19
CABG should be performed in patients with poor LV function who have significant left main
coronary artery stenosis.
Class I B
CABG should be performed in patients with poor LV function who have left main equivalent:
significant (70%) stenosis of proximal LAD and proximal left circumflex artery.
Class I B
CABG should be performed in patients with poor LV function who have proximal LAD stenosis
with 2- or 3-vessel disease.
Class I B
CABG can be performed in patients with poor LV function with significant viable noncontracting,
revascularizable myocardium and without the above anatomic patterns.
Class IIa B
CABG should not be performed in patients with poor LV function without evidence of significant
revascularizable myocardium.
Class III B
CC/AHA guideline update for the diagnosis and management of chronic HF in the adult18
Physicians should recommend coronary revascularization according to recommended guidelines
in patients who have both HF and angina.
Class I A
Patients with CAD and HF should be treated in accordance with recommended guidelines for
chronic stable angina.
Class I C
Coronary arteriography should be performed in patients presenting with HF who have angina or
significant ischemia, unless the patient is not eligible for revascularization of any kind.
Class I B
Coronary arteriography is reasonable for patients presenting with HF who have known or
suspected CAD but do not have angina unless the patient is not eligible for revascularization of
any kind.
Class IIa C
Noninvasive imaging to detect myocardial ischemia and viability is reasonable for patients
presenting with HF who have known or suspected CAD but do not have angina, unless the
patient is not eligible for revascularization of any kind.
Class IIa C
Noninvasive imaging might be considered to define the likelihood of CAD in patients with HF and
LV dysfunction.
Class IIb C
CC/AHA/ASNC 2003 guidelines for the clinical use of cardiac radionuclide imaging21
Predicting improvement in regional and global LV function after revascularization with:
● Stress/redistribution/reinjection thallium-201, rest-redistribution imaging, perfusion plus PET FDG
imaging, resting, sestamibi imaging
Class I B
● Gated-SPECT sestamibi imaging Class IIa B
● Late thallium-201 redistribution after imaging after stress Class IIb B
● Dobutamine RNA, postexercise RNA, postnitroglycerin RNA Class IIb C
Predicting improvement in HF symptoms after revascularization with:
● Perfusion plus PET FDG imaging Class IIa B
Predicting improvement in natural history after revascularization with:
● Thallium-201 imaging (rest-redistribution and stress/redistribution/reinjection), perfusion plus PET
FDG imaging
Class I B
CC/AHA/ASE 2003 guideline update for the clinical application of echocardiography20
Exercise or pharmacologic stress echocardiography for the assessment of myocardial viability
(hibernating myocardium) for planning revascularization
Class I Not ranked
CC/AHA 2002 guideline update for the management of patients with chronic stable angina22
In patients with stable angina, CABG for patients with 3-vessel disease; survival benefit is greater
in patients with abnormal LV function.
Class I A
In patients with stable angina, CABG for patients with 2-vessel disease with significant proximal
LAD CAD and either abnormal LV function (EF 50%) or demonstrable ischemia on noninvasive
testing
Class I B
V, Left ventricular; CABG, coronary artery bypass grafting; ACC, American College of Cardiology; AHA, American Heart Association; LAD, left anterior
escending coronary artery; HF, heart failure; CAD, coronary artery disease; ASNC, American Society for Nuclear Cardiology; PET, positron emission
omography; FDG, fluorodeoxyglucose; SPECT, single photon emission computed tomography; RNA, radionuclide angiography; ASE, American Society of
chocardiography; EF, ejection fraction.
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